Udo Hoffmann,Michael T. Lu,Borek Foldyna,Markella V. Zanni,Julia Karady,Jana Taron,Bingxue K. Zhai,Tricia Burdo,Kathleen V. Fitch,Emma M. Kileel,Kenneth Williams,Carl J. Fichtenbaum,Edgar T. Overton,Carlos Malvestutto,Judith Aberg,Judith Currier,Craig A. Sponseller,Kathleen Melbourne,Michelle Floris-Moore,Cornelius Van Dam,Michael C. Keefer,Susan L. Koletar,Pamela S. Douglas,Heather Ribaudo,Thomas Mayrhofer,Steven K. Grinspoon,Aleen Khodabakhshian,Amy Sbrolla,Beverly E Sha,Christie Lyn Costanza,Claudia A Hawkins,Connor Reynolds,Cornelius N Van Dam,Dan Berrner,David Choi,Jamie L Nemeth,Jeffrey M Jacobson,Joan Gottesman,John Dwyer,John R Koethe,Jorge L Santana,Julie Pasternak,Ken S Ho,Magdalena E Sobieszczyk,Mark Mall,Moises S Huaman,Quynh Truong,Rebecca Fry,Robert T O'Donnell,Roberto C Arduino,Romina Chinchay Collahua,Shaun Barcavage,Shobha Swaminathan,Sigrid Perez-Frontera,Todd Stroberg,

Abstract:Importance: Cardiovascular disease (CVD) is increased among people with HIV (PWH), but little is known regarding the prevalence and extent of coronary artery disease (CAD) and associated biological factors in PWH with low to moderate traditional CVD risk.Objectives: To determine unique factors associated with CVD in PWH and to assess CAD by coronary computed tomography angiography (CTA) and critical pathways of arterial inflammation and immune activation.Design, Setting, and Participants: This cohort study among male and female PWH, aged 40 to 75 years, without known CVD, receiving stable antiretroviral therapy, and with low to moderate atherosclerotic cardiovascular disease (ASCVD) risk according to the 2013 American College of Cardiology/American Heart Association pooled cohort equation, was part of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), a large, ongoing primary prevention trial of statin therapy among PWH conducted at 31 US sites. Participants were enrolled from May 2015 to February 2018. Data analysis was conducted from May to December 2020.Exposure: HIV disease.Main Outcomes and Measures: The primary outcome was the prevalence and composition of CAD assessed by coronary CTA and, secondarily, the association of CAD with traditional risk indices and circulating biomarkers, including insulin, monocyte chemoattractant protein 1 (MCP-1), interleukin (IL) 6, soluble CD14 (sCD14), sCD163, lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), and high-sensitivity C-reactive protein (hsCRP).Results: The sample included 755 participants, with a mean (SD) age of 51 (6) years, 124 (16%) female participants, 267 (35%) Black or African American participants, 182 (24%) Latinx participants, a low median (interquartile range) ASCVD risk (4.5% [2.6%-6.8%]), and well-controlled viremia. Overall, plaque was seen in 368 participants (49%), including among 52 of 175 participants (30%) with atherosclerotic CVD (ASCVD) risk of less than 2.5%. Luminal obstruction of at least 50% was rare (25 [3%]), but vulnerable plaque and high Leaman score (ie, >5) were more frequently observed (172 of 755 [23%] and 118 of 743 [16%], respectively). Overall, 251 of 718 participants (35%) demonstrated coronary artery calcium score scores greater than 0. IL-6, LpPLA2, oxLDL, and MCP-1 levels were higher in those with plaque compared with those without (eg, median [IQR] IL-6 level, 1.71 [1.05-3.04] pg/mL vs 1.45 [0.96-2.60] pg/mL; P = .008). LpPLA2 and IL-6 levels were associated with plaque in adjusted modeling, independent of traditional risk indices and HIV parameters (eg, IL-6: adjusted odds ratio, 1.07; 95% CI, 1.02-1.12; P = .01).Conclusions and Relevance: In this study of a large primary prevention cohort of individuals with well-controlled HIV and low to moderate ASCVD risk, CAD, including noncalcified, nonobstructive, and vulnerable plaque, was highly prevalent. Participants with plaque demonstrated higher levels of immune activation and arterial inflammation, independent of traditional ASCVD risk and HIV parameters.

Quantification of subclinical plaque characteristics and perivascular fat using coronary computed tomography angiography (CCTA) among individuals with human immunodeficiency virus (HIV)

Prevalence and Characterization of Subclinical Coronary Atherosclerotic Plaque with CT among Individuals with HIV: Results from the Canadian HIV and Aging Cohort Study

Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Association of epicardial fat with noncalcified coronary plaque volume and with low attenuation plaque in people with HIV

Association between lipoprotein particle concentration and size and progression of coronary plaque: the MACS Longitudinal Coronary CT angiography study

Coronary artery plaque progression and cardiovascular risk scores in men with and without HIV-infection

Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV

Three Year Follow-Up of HIV Patients Screened with CT Coronary Angiography Identifies more High Risk Plaque and Coronary Events, but less Aggressive Treatment Approaches

Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy

Cardiovascular Risk in People Living with Human Immunodeficiency (HIV) Viremia Suppression in a Young, Mid-Eastern European Population - Preliminary Study

Association Between Inflammation and Coagulation Biomarkers and Carotid Atherosclerosis among Treated People with Human Immunodeficiency Virus

Association Between the Development of Subclinical Cardiovascular Disease and Human Immunodeficiency Virus (HIV) Reservoir Markers in People With HIV on Suppressive Antiretroviral Therapy

Alterations in Th17 Cells and Non-Classical Monocytes as a Signature of Subclinical Coronary Artery Atherosclerosis during ART-Treated HIV-1 Infection

Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States

Coronary Artery Calcification, Atherogenic Lipid Changes, and Increased Erythrocyte Volume in Black Injection Drug Users Infected with Human Immunodeficiency Virus-1 Treated with Protease Inhibitors

Long-term Combination Antiretroviral Therapy is Associated with the Risk of Coronary Plaques in African Americans with HIV Infection.

Circulating Levels of Cardiac Troponin T Are Associated with Coronary Noncalcified Plaque Burden in HIV-infected Adults: a Pilot Study.

HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study

Plasma tissue factor and immune activation are associated with carotid intima-media thickness progression in treated HIV infection